ExEm® Foam Inc. is pleased to be an Exhibitor at the AIUM 45th Annual Advanced OB-GYN Ultrasound Seminar taking place at the Disney Yacht and Beach Club Resorts in Lake Buena Vista, Florida from February 17 – 19, 2022. Visit the ExEm® Foam booth to view a live educational demonstration of the HyFoSy ultrasound tubal patency procedure using ExEm® Foam ((air polymer-type A) intrauterine foam), an innovative, FDA-approved contrast drug that allows for ultrasound tubal patency testing in women with known or suspected infertility. Meet the team and learn about new offerings, reimbursement programs, and product ordering.
About the Advanced Institute of Ultrasound in Medicine (AIUM) and the 45th Annual Advanced OB-GYN Ultrasound Seminar
The American Institute of Ultrasound in Medicine (AIUM) is a multidisciplinary medical association of more than 10,000 physicians, sonographers, scientists, students, and other health care providers. Established in the early 1950’s, the AIUM is dedicated to advancing the safe and effective use of ultrasound in medicine through professional and public education, research, development of guidelines, and accreditation.
The 45th Annual Advanced OB-GYN Ultrasound Seminar is a one-of-a-kind professional development experience that provides attendees with a perfect blend of knowledge, networking, and learning.
About ExEm® Foam (air polymer-type A) intrauterine foam
ExEm® Foam ((air polymer-type A) intrauterine foam) is an innovative, FDA-approved product that offers a less invasive ultrasound procedure, a highly accurate alternative to other tubal patency assessment procedures, like laparoscopy or X-ray HSG. The contrast agent allows for easy recognition of tubal patency using the Foam procedure. During the tubal patency procedure, the foam is infused into the uterus by a healthcare professional to allow for visual assessment of fallopian tubes. If the tubes are patent the foam will appear as a thin, bright white line within the fallopian tubes and spill over the ovaries and into the peritoneal cavity when visualized with ultrasound. If the white line does not appear, the fallopian tubes might be occluded or blocked.
IMPORTANT SAFETY INFORMATION
ExEm® Foam should not be used on patients who are pregnant, have known or suspected lower genital tract inflammation or infection, have had a gynecologic procedure within the last 30 days, have vaginal bleeding, or have known or suspected reproductive tract neoplasia. Common side effects include pelvic and abdominal pain, vasovagal reactions (and associated symptoms such as nausea and faintness), and post-procedure spotting.
Click here for full prescribing information.
About ExEm® Foam Inc
ExEm® Foam Inc is focused on providing solutions to simplify infertility diagnosis and enhance the fertility journey. Drawing on its years of experience, the team develops innovative products that better meet the needs of today’s patient and healthcare professional. ExEm® Foam, the company’s first FDA-approved product, is indicated as a contrast drug for hysterosalpingo foam sonography, also known as HyFoSy, to assess whether there may be a blockage in the fallopian tubes in women with known or suspected infertility. ExEm® Foam has been used in more than 500,000 tubal patency procedures worldwide since it first launched in Europe in 2011. ExEm® Foam Inc is headquartered in Nashville, TN.
For more information, please visit www.exemfoam.com.
